Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and ...

PSGL-1 (P-selectin glycoprotein ligand-1) is an adhesion molecule that is involved in immune cell trafficking in response to tissue injury or inflammation. Verseau discovered that modulation of ...

PSGL-1 plays a key role in regulating late-stage, chronically activated T-cells. ALTB-268 helps to restore the immune system to a state of balance without interfering with cell migration.

Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Monoclonal Antibody - Phase 1a/b Clinical Study of VTX-0811 in Solid Tumors Expected to ...

PSGL-1 was also identified as a potential RE target via genome-wide chromatin immunoprecipitation (ChIP)-sequencing experiments with Kasumi-1 cells and t (8;21)+ patient material. 31 In agreement ...

Yuntao Wu, Professor, Molecular and Microbiology, School of Systems Biology, College of Science, is studying the structure of dicameric repeats (DR) of PSGL-1, a host protein that inhibits HIV ...

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. Immunity, 2016; 44 (5): 1190 DOI: 10.1016/j.immuni.2016.04.015 ...

PSGL-1 VNTR polymorfism was related with site of thrombosis. AB and AC types were more frequent in patients with CVC-R and other vein thrombosis (p=0.02). Besides heterozygosity (AB+AC) relationship ...

Proprietary PSGL-1 monoclonal antibodies induce tumor microenvironment activation, T-cell activation and naïve immune cell recruitment amounting to a coordinated immune attack on tumors.

PSGL-1, a novel target for immunotherapy, can induce macrophage reprogramming and activate a coordinated anti-tumor inflammatory response SHENYANG, China and BEDFORD Mass., Nov. 18, 2019 ...